Vor Biopharma shareholders approve equity plan amendment to 5% annual share increase, elect directors

Vor Biopharma Inc.

Shareholders approved amended 2021 Equity Incentive Plan raising automatic annual share increase from 4% to 5% through 2034.
Robert Ang and Sven (Bill) Ante Lundberg were elected as Class III directors until the 2027 annual meeting.
Ernst & Young ratified as independent auditor for fiscal year 2024.
Plan amendment received 36.8M votes for, 20.9M against; 4.4M broker non-votes.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.